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Abstract
Low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol,
triglycerides, and total cholesterol are heritable, modifiable, risk factors for coronary artery
disease. To identify new loci and refine known loci influencing these lipids, we examined 188,578
individuals using genome-wide and custom genotyping arrays. We identify and annotate 157 loci
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associated with lipid levels at P < 5×10−8, including 62 loci not previously associated with lipid
levels in humans. Using dense genotyping in individuals of European, East Asian, South Asian,
and African ancestry, we narrow association signals in 12 loci. We find that loci associated with
blood lipids are often associated with cardiovascular and metabolic traits including coronary artery
disease, type 2 diabetes, blood pressure, waist-hip ratio, and body mass index. Our results
illustrate the value of genetic data from individuals of diverse ancestries and provide insights into
biological mechanisms regulating blood lipids to guide future genetic, biological, and therapeutic
research.
Introduction
Blood lipids are heritable, modifiable, risk factors for coronary artery disease (CAD)1,2, a
leading cause of death3. Human genetic studies of lipid levels can identify targets for new
therapies for cholesterol management and prevention of heart disease, and can complement
animal studies4,5. Studies of naturally occurring genetic variation can proceed through large-
scale association analyses focused on unrelated individuals or through investigation of
Mendelian forms of dyslipidemia in families6. We previously identified 95 loci associated
with blood lipids, accounting for ~10-12% of the total trait variance4 and showed that
variants with small effects can point to pathways and therapeutic targets that enable
clinically-important changes in blood lipids4,7.
Here, we report on studies of naturally occurring variation in 188,578 European-ancestry
individuals and 7,898 non-European ancestry individuals. Our analyses identify 157 loci
associated with lipid levels at P < 5×10−8, including 62 new loci. Thirty of the 62 loci do not
include genes implicated in lipid biology by previous literature. We tested lipid-associated
SNPs for association with mRNA expression levels, carried out pathway analyses to uncover
relationships between loci, and compared the locations of lipid-associated SNPs with those
of genes and other functional elements in the genome. These results provide direction for
biological and therapeutic research into risk factors for CAD.
Results
Novel loci associated with blood lipid levels
We examined subjects of European ancestry, including 94,595 individuals from 23 studies
genotyped with GWAS arrays4 and 93,982 individuals from 37 studies genotyped with the
Metabochip array8 (Supplementary Table 1 and Supplementary Fig. 1). The Metabochip
includes variants representing promising loci from our previous GWAS (14,886 SNPs) and
from GWAS of other CAD risk factors and related traits (50,459 SNPs), variants from the
1000 Genomes Project9 and focused resequencing10 efforts in 64 previously associated loci
(28,923 SNPs), and fine-mapping variants in 181 loci associated with other traits (93,308
SNPs). In cases where Metabochip and GWAS array data were available for the same
individuals, we used Metabochip data to ensure key variants were directly genotyped, rather
than imputed.
We excluded individuals known to be on lipid lowering medications and evaluated the
additive effects of each SNP on blood lipid levels after adjusting for age and sex. Genomic
control values11 for the initial meta-analyses were 1.10 – 1.15, low for a sample of this size,
indicating that population stratification should have only a minor impact on our results
(Supplementary Fig. 2). After genomic control correction, 157 loci associated with blood
lipid levels were identified (P < 5×10−8), including 62 new loci (Tables 1A-D, Figure 1,
Supplementary Tables 2 and 3). Loci were >1 Mb apart and nearly independent (r2 < 0.10).
Of the 62 novel loci, 24 demonstrated the strongest evidence of association with HDL
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cholesterol, 15 with LDL cholesterol, 8 with triglyceride levels, and 15 with total cholesterol
(Supplementary Fig. 3). Several of these loci were validated by a similar extension based on
GLGC GWAS results 12.
The effects of newly identified loci were generally smaller than in earlier GWAS
(Supplementary Fig. 4). For the 62 newly identified variants, trait variance explained in the
Framingham offspring were 1.6% for HDL cholesterol, 2.1% for triglycerides, 2.4% for
LDL cholesterol, and 2.6% for total cholesterol.
Overlap of genetic discoveries and prior knowledge
To investigate connections between our new loci and known lipid biology, we first
catalogued genes within 100 kb of the peak associated SNPs and searched PubMed and
OMIM for occurrences of these gene names and their aliases in the context of relevant
keywords. After manual curation, we identified at least one strong candidate in 32 of the 62
loci (52%) (Supplementary Table 4). For the remaining 30 loci, we found no literature
support for the role of a nearby gene on blood lipid levels. This search highlighted genes
whose connections to lipid metabolism have been extensively documented in mouse models
(such as VLDLR13 and LRPAP113) and human cell lines (such as VIM14), as well as
candidates whose connection to lipid levels is more recent, such as VEGFA. For the latter,
recent studies of VEGFB have suggested that vascular endothelial growth factors have an
unexpected role in the targeting of lipids to peripheral tissues15, which we corroborate by
associating variants near VEGFA with blood triglyceride and HDL levels.
Multiple types of evidence supported several literature candidates (Supplementary Table 2).
For example, VLDLR is categorized by Gene Ontology16 in the retinoid × nuclear receptor
(RXR) activation pathway, which also includes genes (APOB, APOE, CYP7A1, APOA1,
HNF1A, HNF4A) in previously implicated loci4. However, since these additional sources of
evidence build on overlapping knowledge they are not truly independent.
To estimate the probability of finding ≥32 literature supported candidates after automated
search and manual review of results, we repeated our text-mining literature search using 100
permutations of SNPs matched for allele frequency, distance to the nearest gene, and
number of linkage disequilibrium proxies. To approximate hand-curation of the text-mining
results, we focused on genes implicated by 3 or more publications (25 in observed data, 8.7
on average in control SNP sets, P = 8×10−8).
Pathway analyses
We performed a gene-set enrichment analysis, using MAGENTA17, to evaluate over-
representation of biological pathways among associated loci. Across the 157 loci,
MAGENTA identified 71 enriched pathways. These pathways included at least one gene in
20 of our newly identified loci (Supplementary Table 5). Examples include DAGLB
(connected to previously associated loci by genes in the triglyceride lipase activity pathway),
INSIG2 (connected by the cholesterol and steroid metabolic process pathways), AKR1C4
(connected by the steroid metabolic process and bile acid biosynthesis pathways), VLDLR
(connected by the retinoic × receptor activation and lipid transport pathways, among others),
PPARA, ABCB11, and UGT1A1 (three genes assigned to pathways implicated in activation
of nuclear hormone receptors, which play an important role in lipid metabolism through the
transcriptional regulation of genes in sterol metabolic pathways18). Among the 16 loci
where literature review and pathway analysis both suggested a candidate, the predictions
overlapped 14 times (Supplementary Table 2; by chance, we expect 6.6 overlapping
predictions, P = 1×10−5).
Willer et al. Page 9
Nat Genet. Author manuscript; available in PMC 2014 May 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Protein-protein interactions
We assessed evidence for physical interactions between proteins encoded near our
associated SNPs using DAPPLE19. We found an excess of direct protein-protein interactions
for genes in loci associated with LDL (10 interactions, P = 0.0002), HDL (8 interactions, P =
0.002), and total cholesterol (6 interactions, P = 0.017), but not for triglycerides (2
interactions, P = 0.27) (Supplementary Fig. 5). Most of the interactions involved genes at
known loci (such as the interaction network connecting PLTP, APOE, APOB, and LIPC) or
highlighted the same genes as literature and pathway analyses (such as those connecting
VLDLR, APOE, APOB, CETP, and LPL). Among novel loci, we identified a link between
AKT1 and GSK3B. GSK3B has been shown to play a role in energy metabolism20 and its
activity is regulated by AKT1 through phosphorylation21. Literature review also supported a
role in blood lipid levels for these two genes.
Regulation of gene expression by associated variants
Many complex trait associated variants act through the regulation of gene expression. We
examined whether our 62 novel variants were associated with expression levels of nearby
genes in liver, omental fat, or subcutaneous fat. Fifteen were associated with expression of a
nearby transcript with P < 5×10−8 (Supplementary Table 6) and, in seven, the lipid-
associated variant was in strong disequilibrium with the strongest expression-quantitative
trait locus (eQTL) for the region (r2 > 0.8). In three of these loci, literature search also
prioritized candidate genes. In all three, eQTL analysis and literature review identified the
same candidate (DAGLB, SPTLC3, and PXK, P = 0.05). For the remaining four loci (near
RBM5, ADH5, TMEM176A, and GPR146), analysis of expression levels identified
candidates that were not supported by literature or pathway analyses.
Coding variation
In some loci where previous coding variant association studies were inconclusive, we now
find convincing evidence of association, demonstrating the benefits of the large sample sizes
achievable by collaboration. For example, in the APOH locus22, our most strongly
associated variant is rs1801689 (APOH C325G, P = 1×10−11 for LDL cholesterol). Overall,
at 15 of the 62 new loci, there is at least one nonsynonymous variant within 100kb and in
strong (r2>0.8) linkage disequilibrium with the index SNP (Supplementary Table 7)(18 loci
with no restrictions on distance). This ~30% overlap between associated loci and coding
variation is similar to that in other complex traits9. Unexpectedly, in the 11 loci where a
candidate was suggested by literature review and by coding variation, the two coincided
seven times (P = 0.03 compared to expected chance overlap of 3.8 times); thus, agreement
between literature and coding variation was less significant than for eQTL and pathway
analysis or protein-protein interactions.
Overlap between association signals and regulators of transcription in liver
Despite our efforts, 18 of the 62 new loci remain without prioritized candidate genes. The
liver is an important hub of lipid biosynthesis and there is evidence that lipid loci might be
associated with changes in gene regulation in liver cells23. Using ENCODE data23, we
evaluated whether associated SNPs overlapped experimentally annotated functional
elements identified in HepG2 cells, a commonly used model of human hepatocytes. To
determine significance, we generated 100,000 lists of permuted SNPs, matched for minor
allele frequency, distance to the nearest gene, and number of SNPs in r2 > 0.8 (described in
Methods). In HepG2 cells, lipid-associated SNPs were enriched in eight of the 15 functional
chromatin states defined by Ernst et al.24 (P < 1×10−5; Supplementary Table 8). The
strongest enrichment was in regions with “strong enhancer activity” (3.7-fold enrichment, P
= 2×10−25; Supplementary Table 9). In the other eight cell types examined by Ernst et al., no
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more than three functional chromatin states showed evidence for enrichment (and, when
present, enrichment was weaker).
We proceeded to investigate the overlap between lipid loci and functional marks in HepG2
cells in more detail (Supplementary Table 9). Notable regulatory elements showing
significant overlap with lipid loci included histone marks associated with active regulatory
regions (H3K27ac, P = 3×10−20; H3K9ac, P = 3×10−22), promoters (H3K4me3, P =
2×10−15, H3K4me2, P = 8×10−12), transcribed regions (H3K36me3, P = 4×10−14),
indicators of open chromatin (FAIRE, P = 5×10−9; DNase, P = 2×10−4), and regions that
interact with transcription factors HNF4A (P = 6×10−10) and CEBP/B (P = 1×10−5).
Overall, 56 of our 62 new loci contained at least one SNP that overlaps a functional mark24
and/or chromatin state23 highlighted in Supplementary Table 9, including all but 3 of the
loci where no candidates were suggested by literature review or analyses of pathways,
coding variation, or gene expression (Supplementary Table 10).
Initial fine-mapping of 65 lipid-associated loci
Previous fine-mapping of five LDL-associated lipid loci found that variants showing the
strongest association were often substantially different in frequency and effect size from
those identified in GWAS10. Metabochip genotypes enabled us to carry out an initial fine-
mapping analysis for 65 loci: 60 selected for fine-mapping based on our previous study4 and
5 nominated for fine-mapping because of association to other traits.
For each of these loci, we identified the most strongly associated Metabochip variant and
evaluated whether it (a) reached genome-wide significant evidence for association (to avoid
chance fluctuations in regions where the signal was relatively weak) and (b) was different
from the GWAS index SNP in terms of frequency and effect size (operationalized to r2 < 0.8
with the GWAS index SNP). In the European samples, fine-mapping identified eight loci
where the fine-mapping signal was clearly different from the GWAS signal (Supplementary
Table 11). The two largest differences were at the loci near PCSK9 (top GWAS variant with
minor allele frequency f = 0.24 and P = 9×10−24; fine-mapping variant with f = 0.03, P =
2×10−136) and APOE (GWAS variant f = 0.20, P = 3×10−44, fine-mapping variant f = 0.07,
P = 3×10−651), consistent with Sanna et al10. Large differences were also observed near
LRP4 (GWAS f = 0.17, P = 8×10−14; fine-mapping f = 0.35, P = 1×10−26), IGF2R (GWAS f
= 0.16, P = 7×10−9; fine-mapping f = 0.37, P = 2×10−13), NPC1L1 (GWAS f = 0.27, P =
2×10−5; fine-mapping f = 0.24, P = 1×10−12), ST3GAL4 (GWAS f = 0.26, P = 2×10−6; fine-
mapping f = 0.07, P = 6×10−11), MED1 (GWAS f = 0.37, P = 3×10−5; fine-mapping f =
0.24, P = 2×10−10), and COBLL1 (GWAS f = 0.12, P = 2×10−6; fine-mapping f = 0.11, P =
6×10−9). Thus, although the large changes observed by Sanna et al10 after fine-mapping are
by no means unique, they are not typical. Except for the R46L variant in PCSK9, the
variants showing strongest association in fine-mapped loci all had minor allele frequency > .
05.
We also attempted fine-mapping in African (N=3,263), East Asian (N=1,771), and South
Asian (N=4,901) ancestry samples. Despite comparatively small samples, ancestry-specific
analyses identified SNPs clearly distinct from the original GWAS variant in five loci
(Supplementary Table 11). These were: APOE, consistent with European ancestry analyses
above; three loci where differences in linkage disequilibrium between populations enabled
fine-mapping in African (SORT1, LDLR) or East Asian (APOA5) ancestry samples; and
CETP, where an African-specific variant was present. For CETP, SORT1, and APOA5,
results are consistent with other fine-mapping and functional studies7,7,25,26.
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Association of lipid loci with metabolic and cardiovascular traits
To evaluate the role of the 157 loci identified here on related traits, we evaluated the most
strongly associated SNPs for each locus in genetic studies of coronary artery disease (CAD,
N=114,590 including 37,653 cases)27,28, type 2 diabetes (T2D, N=47,117 including 8,130
cases)29, body mass index (BMI, N=123,865 individuals)30 and waist-hip ratio (WHR,
N=77,167 individuals)31, systolic and diastolic blood pressure (SBP and DBP, N=69,395
individuals)32, and fasting glucose (N=46,186 non-diabetics)33. We observed an excess of
SNPs nominally associated (P < 0.05) with all these traits: a 5.1 fold excess for CAD (40
nominally significant loci, P = 2×10−19), a 4.1 fold excess for BMI (32 loci, P = 1×10−11),
3.7 fold excesses for DBP (29 loci, P = 1×10−9), a 3.4 fold excess for WHR (27 loci, P =
1×10−9), a 2.5 fold excess for SBP (20 loci, P = 1×10−4), a 2.3 fold excess for T2D (18 loci,
P = 0.001), and a 2.2 fold excess for fasting glucose (17 loci, P = 3×10−3) (Supplementary
Table 12). Interestingly, among the novel loci, we observed greater overlap with BMI, SBP,
and DBP (9 overlapping loci each) than with CAD (8 overlapping loci). Among new loci,
the two SNPs showing strongest association to CAD map near RBM5 (rs2013208, PHDL =
9×10−12, PCAD = 7×10−5) and CMTM6 (rs7640978, PLDL = 1×10−8, PCAD = 4×10−4).
We tested whether the LDL-, total cholesterol- or triglyceride-increasing allele, or HDL-
decreasing allele was associated with increased risk of cardiovascular disease or related
metabolic outcomes; the direction of effect of each locus was categorized according to the
primary association signal at the locus, as in Tables 1A-D. We observed association with
increased CAD risk (104/149, P = 1×10−6), SBP (96/155, P = 2.7×10−3) and WHR adjusted
for BMI (92/154, P = 0.019). There were many instances where a single locus was
associated with many traits. These included variants near FTO, consistent with previous
reports34; near VEGFA (associated with triglyceride levels, CAD, T2D, SBP, and DBP),
near SLC39A8 (associated with HDL cholesterol, BMI, SBP, and DBP), and near MIR581
(associated with HDL cholesterol, BMI, T2D, and DBP). In some cases, like FTO, a strong
association with BMI or another phenotype generates weaker association signals for other
metabolic traits34. In other cases, like SORT1, a primary effect on lipid levels may mediate
secondary association with other traits, like CAD7.
Association of individual lipids with coronary artery disease
Epidemiological studies consistently show high total cholesterol and LDL cholesterol levels
are associated with increased risk of CAD, whereas high HDL cholesterol levels are
associated with reduced risk of CAD35. In genetic studies, the connection between LDL
cholesterol and CAD is clear, whereas the results for HDL cholesterol levels are more
equivocal36-38. In our data, trait increasing alleles at the loci showing strongest association
with LDL cholesterol (31 loci), triglycerides (30 loci), or total cholesterol (38 loci) were
associated with increased risk of CAD (P = 2×10−12, P = 2×10−16, and P = 0.006).
Conversely, trait decreasing alleles at loci showing the strongest association with HDL
cholesterol (64 loci), were associated with increased CAD risk with P = 0.02. When we
focused on loci uniquely associated with LDL cholesterol (12 loci where P > .05 for other
lipids), triglycerides (6 loci), or HDL cholesterol (14 loci), only the LDL association
remained significant (P = 0.03).
To better explore how associations with individual lipid levels related to CAD risk, we used
linear regression to test whether association with lipid levels could predict impact on CAD
risk. In this analysis, the effect on CAD of 149 lipid loci (CAD results were not available for
8 SNPs) was correlated with LDL (Pearson r=0.74, P = 7×10−6) and triglyceride (Pearson
r=0.46, P = 0.02) effect sizes, but not HDL effect sizes (Pearson r=−9×10−4, P = 0.99;
Supplementary Fig. 6). Since most variants affect multiple lipid fractions (Figure 1),
dissecting the relationship between lipid level and CAD effects requires multivariate
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analysis. In a companion manuscript, we use multivariate analysis and detailed examination
of triglyceride associated loci to show that increased LDL and triglyceride levels, but not
HDL, appear causally related to CAD risk.
Evidence for additional loci, not yet reaching genome-wide significance
To evaluate evidence for loci not yet reaching genome-wide significance, we compared
direction of effect in GWAS and Metabochip analyses of non-overlapping samples, outside
the 157 genome-wide significant loci. Among independent variants (r2 < 0.1) with P < 0.1 in
the GWAS-only analysis, a significant excess were concordant in direction of effect for
HDL (62.9% in 1,847 SNPs, P < 10−16), LDL (58.6% of 1,730 SNPs, P < 10−16),
triglyceride levels (59.1% of 1,783 SNPs, P < 10−16), and total cholesterol (61.0% of 1,904
SNPs, P < 10−16), suggesting many additional loci to be discovered in future studies.
Discussion
Molecular understanding of the genes and pathways that modify blood lipid levels in
humans will facilitate the design of new therapies for cardiovascular and metabolic disease.
This understanding can be gained from studies of model organisms, in vitro experiments,
bioinformatic analyses, and human genetic studies. Here, we demonstrate association
between blood lipid levels and 62 new loci, bringing the total number of lipid-associated loci
to 157 (See Tables 1A-D and Figure 1). All but one of the loci identified here include
protein-coding genes within 100 kb of the SNP showing strongest association. While 38 of
the 62 new loci include genes whose role in blood lipid levels is supported by literature
review or analysis of curated pathway databases, the remainder includes only genes whose
role on blood lipid levels has not been documented.
In total, there are 240 genes within 100 kb of one of our 62 new lipid-associated loci –
providing a daunting challenge for future functional studies. Prioritizing on the basis of
literature review, pathway analysis, regulation of mRNA expression levels, and protein
altering variants suggests that 70 genes in 44 of the 62 new loci might be the focus of the
first round of functional studies (summarized in Supplementary Table 2). While we found
significant overlap, different sources of prioritization sometimes disagreed. This result
suggests that truly understanding causality will be very challenging. The Supplementary
Note includes an interpreted digest of genes highlighted by our study. Clearly, a range of
approaches will be needed to follow-up these findings. To illustrate possibilities, consider U.
S. Patent Application #20,090,036,394 disclosing that, in the mouse, knockout of Gpr146
modifies blood lipid levels. Here, we show that variants near the human homologue of this
gene, GPR146, are associated with levels of total cholesterol – providing an added incentive
for studies of GPR146 inhibitors in humans. GPR146 encodes a G-protein coupled receptor
– an attractive pharmaceutical target – so it is tempting to speculate that, one day,
pharmaceutical inhibition of GPR146 may modify cholesterol levels and reduce risk of heart
disease.
Each locus typically includes many strongly associated (and potentially causal) variants. Our
fine-mapping results illustrate how genetic analysis of large samples and individuals of
diverse ancestry can help focus the search for causal variants. In our fine-mapping analysis
of 65 lipid-associated loci, we were able to separate the strongest signal in a region from the
prior GWAS signal in 12 instances. In three of these 12 instances, fine-mapping was enabled
by analysis of a few thousand African or East Asian ancestry individuals, whereas in the
remaining instances, fine-mapping was possible through examination of nearly 100,000
European ancestry samples. A more detailed fine-mapping exercise, including imputation of
variants from emerging very large reference panels, may help refine the location of
additional signals.
Willer et al. Page 13
Nat Genet. Author manuscript; available in PMC 2014 May 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Lipid-associated loci were strongly associated with CAD, T2D, BMI, SBP, and DBP. In
univariate analyses, we found that impact on LDL and triglycerides all predicted association
with CAD, but HDL did not. In a more detailed multivariate investigation, a companion
manuscript shows that our data is consistent with the hypothesis that both LDL and
triglycerides, but not HDL, are causally related to CAD risk. HDL, LDL, and triglycerides
levels summarize aggregate levels of different lipid particles, each with potentially distinct
consequences for CAD risk. We evaluated association of our loci with lipid subfractions in
2,900 individuals from the Framingham Heart Study (Supplementary Table 13,
Supplementary Fig. 7) and with sphingolipids, which are components of lipid membranes in
cells, in 4,034 individuals from five samples of European ancestry39 (Supplementary Table
14). The results suggest HDL-associated variants can have a markedly different impact on
these sub-phenotypes. For example, among HDL loci, variants near LIPC were strongly
associated with plasmalogen levels (P < 10−40), variants near ABCA1 were associated with
sphingomyelin levels (P < 10−5), and variants near CETP – which show the strongest
association with HDL cholesterol overall – were associated with neither of these. Detailed
genetic dissection of these sub-phenotypes in larger samples, could lead to functional
groupings of HDL-associated variants that reconcile the results of genetic studies (which
show no clear connection between HDL cholesterol-associated variants and CAD risk) and
epidemiologic studies (which show clear association between plasma HDL levels and CAD
risk).
In summary, we report the largest genetic association study of blood lipid levels yet
conducted. The large number of loci identified, the many candidate genes they contain, and
the diverse proteins they encode generate new leads and insights into lipid biology. It is our
hope that the next round of genetic studies will build on these results, using new sequencing,
genotyping, and imputation technologies to examine rare loss-of-function alleles and other
variants of clear functional impact to accelerate the translation of these leads into
mechanistic insights and improved treatments for CAD.
Online Methods
Samples studied
We collected summary statistics for Metabochip SNPs from 45 studies. Among these, 37
studies consisted primarily of individuals of European ancestry (see Supplementary Table 1
and Supplementary Note for details), including both population-based studies and case-
control studies of CAD and T2D. Another 8 studies consisted primarily of individuals with
non-European ancestry: two studies of South Asian descent, AIDHS/SDS (N=1,516) and
PROMIS (N=3,385); two studies of East Asian descent, CLHNS (N=1,771) and TAI-CHI
(N=7044); and five studies of recent African ancestry, MRC/UVRI GPC (N=1,687) from
Uganda, SEY (N=426) from the Caribbean, and FBPP (N=1,614, TG results unavailable),
GXE (N=397), and SPT (N=838) from the United States (more details in Supplementary
Table 1 and Supplementary Note).
Genotyping
We genotyped 196,710 genetic variants prioritized on the basis of prior GWAS for
cardiovascular and metabolic phenotypes using the Illumina iSelect Metabochip8
genotyping array. To design the Metabochip, we used our previous GWAS of ~100,000
individuals4 to prioritize 5,023 SNPs for HDL cholesterol, 5,055 for LDL cholesterol, 5,056
for triglycerides, and 938 for total cholesterol. These independent SNPs represent most loci
with P < .005 in our original GWAS for HDL cholesterol, LDL cholesterol and triglycerides
and with P < .0005 for total cholesterol. An additional 28,923 SNPs were selected for fine-
mapping of 65 previously identified lipid loci. The Metabochip also included 50,459 SNPs
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prioritized based on GWAS of non-lipid traits and 93,308 SNPs selected for fine-mapping of
loci associated with non-lipid traits (5 of these loci were associated with blood lipids by the
analyses described here).
Phenotypes
Blood lipid levels were typically measured after > 8 hours of fasting. Individuals known to
be on lipid-lowering medication were excluded when possible. LDL cholesterol levels were
directly measured in 10 studies (24% of total study individuals) and estimated using the
Friedewald formula40 in the remaining studies. Trait residuals within each study cohort were
adjusted for age, age2, and sex, and then quantile normalized. Explicit adjustments for
population structure using principal component41 or mixed model approaches42 were carried
out in 24 studies (35% of individuals); all studies were adjusted using genomic control prior
to meta-analysis11. In studies ascertained on diabetes or CVD status, cases and controls were
analyzed separately (Supplementary Table 1). All meta-analyses were limited to a single
ancestral group (e.g. European only).
Primary statistical analysis
Individual SNP association tests were performed using linear regression with the inverse
normal transformed trait values as the dependent variable and the expected allele count for
each individual as the independent variable. These analyses were performed using PLINK
(26 samples, 53% of the total number of individuals), SNPTEST (4 samples, 20% of
individuals), EMMAX (9 samples, 14% of individuals), Merlin (4 samples, 9% of
individuals), GENABEL (1 sample, 3% of individuals), and MMAP (1 sample, 1% of
individuals) (Supplementary Table 1).
Meta-analysis
Meta-analysis was performed using the Stouffer method43,44, with weights proportional to
the square root of the sample size for each sample. To correct for inflated test statistics due
to potential population stratification, we first applied genomic control to each sample and
then repeated the procedure with initial meta-analysis results. For GWAS samples, we used
all available SNPs when estimating the median test statistic and inflation factor λ. For
Metabochip samples, we used a subset of SNPs (N = 7,168) that had P-values > 0.50 for all
lipid traits in the original GWAS, expecting that the majority of these would not be
associated with lipids and would behave as null variants in the Metabochip samples. Signals
were considered to be novel if they reached a P-value < 5×10−8 in the combined GWAS and
Metabochip meta-analysis and were >1 Mb away from the nearest previously described lipid
locus and other novel loci. We used only European samples for the discovery of novel
genome-wide significant loci. The non-European samples were meta-analyzed and
examined only for fine-mapping analyses.
Quality control
To flag potentially erroneous analyses, we carried out a series of quality control steps.
Average standard errors for association statistics from each study were plotted against study
sample size to identify outlier studies. We inspected allele frequencies to ensure all analyses
used the same strand assignment of alleles. We evaluated whether reported statistics and
allelic effects were consistent with published findings for known loci. Genomic control
values for study specific analyses were inspected, and all were <1.20. Finally, within each
study, we excluded variants for which the minor allele was observed <7 times.
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Proportion of trait variance explained
We estimated the increase in trait variance explained by novel loci in the Framingham
cohort (N=7,132) using three models for each trait-residual: 1) lead and secondary SNPs
from the previously published loci4 and 2) previously published lipid loci plus newly
reported loci; and 3) newly reported loci. We regressed lipid residuals on these sets of SNPs
using the lme kinship package in R.
Initial automated review of the published literature
An initial list of candidates within each locus was generated with Snipper (http://
csg.sph.umich.edu/boehnke/snipper/) and then subjected to manual review. For each locus,
Snipper first generates a list of nearby genes and then checks for the co-occurrence of the
corresponding gene names and selected search terms (“cholesterol”, “lipids”, “HDL”,
“LDL”, or “triglycerides”) in published literature and OMIM. We supplemented this
approach with traditional literature searches using PubMed and Google.
Generating permuted sets of non-associated SNPs
To estimate the expected chance overlap between literature searches and our loci, we
generated lists of permuted SNPs. To generate these lists, we first identified all non-
associated lipid SNPs (P > 0.10 for any of the 4 lipid traits) and created bins based on 3
statistics: minor allele frequency, distance to the nearest gene, and number of SNPs with r2 >
0.8. For each index SNP, we identified 500 non lipid-associated SNPs that fell within the
same 3 bins and randomly selected one SNP for each permuted list.
Pathway analyses
To investigate if lipid-associated variants overlapped previously annotated pathways, we
used gene set enrichment analysis (GSEA), as implemented in MAGENTA17 using the
meta-analysis of all studies, including GWAS and Metabochip SNPs. Briefly, MAGENTA
first assigns SNPs to a given gene when within 110 kb upstream or 40 kb downstream of
transcript boundaries. The most significant SNP P-value within this interval is then adjusted
for confounders (gene size, marker density, LD) to create a gene association score. When the
same SNP is assigned to multiple genes, only the gene with the lowest score is kept for
downstream analyses. Subsequently, MAGENTA attaches pathway terms to each gene using
several annotation resources, including GO, PANTHER, Ingenuity, and KEGG. Finally, the
genes are ranked on their gene association score, and a modified GSEA test is used to test
the null hypothesis that all gene score ranks above a given rank cutoff are randomly
distributed with regard to a given pathway term (and compared to multiple randomly
sampled gene sets of identical size). We evaluated enrichment by using a rank cutoff of 5%
of the total number of genes. A minimum of 10,000 gene set permutations were performed,
and up to 1,000,000 permutations for GSEA P-values below 1×10−4.
We used the Disease Association Protein–Protein Link Evaluator package (DAPPLE; http://
www.broadinstitute.org/mpg/dapple/dapple.php) to examine evidence for protein-protein
interaction networks connecting genes across different lipid loci. This analysis included the
62 novel loci as well as the 95 previously known loci; we focus our discussion on pathways
that included one or more genes from novel loci.
Cis-expression quantitative trait locus analysis
To determine whether lipid-associated SNPs might act as cis-regulators of nearby genes, we
examined association with expression levels of 39,280 transcripts in 960 human liver
samples, 741 human omental fat samples, and 609 human subcutaneous fat samples. Tissue
samples were collected postmortem or during surgical resection from donors; tissue
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collection, DNA and RNA isolation, expression profiling, and genotyping were performed
as described45. MACH was used to obtain imputed genotypes for ~2.6 million SNPs in the
HapMap release 22 for each of the samples. We examined the correlation between each of
the 62 new index SNPs and all transcripts within 500 kb of the SNP position, performing
association analyses as previously described46.
Functional annotation of associated variants
We attempted to identify lipid-associated SNPs that fall in important regulatory domains.
We initially created a list of all potentially causal variants by selecting index SNPs at loci
identified in this study or in Teslovich et al4. We then selected any variant in strong linkage
disequilibrium (r2 > 0.8 from 1000 Genomes or HapMap) with each index SNP. We
compared the position of the index SNPs and their proxies to previously described
functional marks23,24. To assess the expected overlap with functional marks, we created
100,000 permuted sets of non-associated SNPs (see above) and evaluated permuted SNP
lists for overlap with functional domains. We estimated a P-value for each functional
domain as the proportion of permuted sets with an equal or greater number of loci
overlapping functional domains (for large P-values). For small P-values we used a normal
approximation to the empirical overlap distribution to estimate P-values.
Association with lipid subfractions
Lipoprotein fractions for Women’s Genome Health Study (WGHS) samples (N = 23170)
were measured using the LipoProtein-II assay (Liposcience Inc. Raleigh, NC) and
Framingham Heart Study Offspring samples (N = 2900) were measured with the
LipoProtein-I assay (Liposcience Inc. Raleigh, NC)47. Additional information on sub-
fraction measurements can be found in Supplementary Fig. 7. Log transformations were
used for non-normalized traits. All models were adjusted for age, sex, and PCs. The genetic
association analysis of WGHS used SNP genotypes imputed from the HapMap r22 CEU
reference panel using MACH. 16,730 out of 23,170 WGHS participants were fasting for 8
hours prior to blood draw (72.2%).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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FIGURE 1. Overlap between loci associated with different lipid traits
This Venn Diagram illustrates the number of loci that show association with multiple lipid
traits. The number of loci primarily associated with only one trait is listed in parentheses
after the trait name and the locus name is listed below in italics. Loci that show association
with two or more traits are shown in the appropriate section.
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